
Senators Elizabeth Warren and Tina Smith have reintroduced the Pharmaceutical Supply Chain Defense and Enhancement Act originally established in 2020.

Senators Elizabeth Warren and Tina Smith have reintroduced the Pharmaceutical Supply Chain Defense and Enhancement Act originally established in 2020.

A study found that patients with medication-overuse headache and neck pain experience earlier onset of primary headache and decreased quality of life.

Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.

A conversation with Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences.

Researchers explored the impacts of natural bioactive compounds for the treatment of acute pancreatitis.

Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.

Authors concluded that that the benefit of the vaccine in preventing long COVID is due mainly to the fact it mitigates the risk of infection.

Although the drug fell short of its 25% expected weight loss, results are still promising for people with overweight or obesity.

With pressure from the House GOP, expected PBM reform was not included in Congress’ end-of-year spending package.

Recent upticks of the bird flu virus in both dairy cattle and humans have also led to a state of emergency in California.

The lawsuit alleges that the company knowingly violated both the Controlled Substances Act and the False Claims Act.

MannKind announced results from the INHALE-1 study that examined Afrezza in children and adolescents with diabetes.

The American Pharmacists Association announced the inclusion of pharmacist-backed PBM reform in Congress’ end of the year spending package.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic, discusses her career and how biosimilars will impact the pharmacy profession in the coming years.

Student pharmacists who wore a continuous glucose monitor had a higher average counseling score during an encounter with a patient and a higher overall confidence score.

A conversation with Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic.

Triptans are used to treat acute migraine and cluster headaches.

Treatment of comorbidities may help patients overcome resistance or refractoriness to migraine therapies.

Drug Topics met with Lourdes Cross, PharmD, BCACP, CDCES, to discuss pharmacists’ role in managing patients’ chronic obstructive pulmonary disease.

Two posters presented at the meeting looked into the topic CGMs in diabetes care.

Experts conducted a study to better understand how ambulatory care pharmacist services impacted patient outcomes, provider workload, and access to care.

Drug Topics met with Amanuel Kehasse, PharmD, PhD, to discuss the barriers surrounding biosimilar implementation in the prescription drug market.

Vtama from Organon was previously approved in May 2022 to treat plaque psoriasis in adults.

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.

Kathryn Litten, PharmD, discussed the pharmacist’s role in helping patients manage metabolic dysfunction-associated steatotic liver disease.

US Senators introduced the bipartisan bill addressing pharmacy benefit managers and their affiliated pharmacies.

Nina Vadiei, PharmD, BCPP, discusses some of the challenges she faces working with forensic patients who have been charged with a crime and have severe mental illness.

Researchers presented the community-wide benefits of a collaborative pharmacy-driven vaccine clinic in an urban setting.

Research found that SGLT2 inhibitors were associated with a lower risk of major cardiovascular events or hospitalization for heart failure.